Pianist Arash Behzadi Releases New Album 'Elsewhere'
A Pianist with a Healing Touch
Toronto, ON, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Personal loss, yearning, passionate love, heartache, prescient dreams and healing journeys are central to the powerful musical narratives in pianist/composer Arash Behzadi's newest album, Elsewhere , which will be released October 27th 12 a.m. EST.
Arash Behzadi's solo piano compositions are musical narratives that reflect the trials and triumphs of life through deeply personal stories and transformational experiences which he invites his audience to share. Elsewhere is reflective of the gamut of human experience and emotion. It's about the drama of life.
"I feel that my music is universal and timeless," Behzadi says. "It never ages. And because of that people feel an instant connection. It speaks to people of all ages. It opens up emotions and it heals."
In a series of recent visits to Bali, Behzadi found an unexpected inner peace and tranquillity in the timeless island's ancient sacred temples and its gentle people.
His own personal transformation has inspired him to share his passion for the healing powers of music which we see reflected in pieces on the album such as "Heartfelt," an intensely personal composition, peaceful yet powerful, exposing a touching vulnerability yet confident in its execution. Other pieces were designed to bring about the healing of relationships and reunite people who had grown apart.
Because the piano has the capacity to mirror human experience in all its complexities, from moments of profound sadness and loss to exhilaration and new beginnings, Behzadi envisions his compositions serving at many levels - from movie scores to beneficial and creative adjuncts to the work of physicians and therapists and live yoga meditation.
Behzadi is an exciting new Persian-Canadian talent, a New Age pianist/composer with a global audience. He has performed worldwide including the renowned Bali Spirit Festival, in Geneva, New York, Dubai and at the 2015 Pan Am Games as well as the Tirgan Festival in Toronto. Elsewhere is his second album following the successful release of With Closed Eyes along with several music videos filmed in Bali, Geneva, Florida, Northern Ontario and Toronto, all of which can be viewed on his website.
*We ask for the link not to be shared with the general public until the release date. The link is for media purposes only.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/706ce19f-66ff-49dd-aa65-bd8f5eb71ab6
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/fc0435da-9120-472f-9926-2cc4ee85cad5
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Arash Behzadi via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Stillfront Group AB: Stillfront one of Sweden's fastest growing companies19.10.2017 11:00 | Pressmeddelande
PRESS RELEASE October 19, 2017 Stillfront included in Deloitte Sweden Technology Fast 50 Stillfront has been included in Deloitte Sweden Technology Fast 50. Deloitte Sweden Technology Fast 50 is a ranking of Sweden's 50 fastest growing technology companies, based on revenue growth over the last four years. The ranking includes public and private companies, large and small, in all areas of technology, from internet specialists to biotech, digital media technology to life sciences, computers to semiconductors and software to telecommunications. Please find more detailed information (in Swedish) on www.deloitte.se/fast50. Stillfront has since the IPO in the autumn of 2015 recorded a continuous high and profitable growth in revenues rolling 12 months. Since the IPO, Stillfront has increased the number of so-called core products (i.e. games that have more than 5 MSEK in annual revenue rate) from four to fourteen and the number of studi
Stillfront Group AB: Stillfront ett av Sveriges snabbast växande teknikföretag19.10.2017 11:00 | Pressmeddelande
PRESSMEDDELANDE 2017-10-19 Stillfront med i Deloitte Sweden Technology Fast 50 Stillfront har kommit med i Deloitte Sweden Technology Fast 50 2017. Deloitte Sweden Technology Fast 50 är en ranking av Sveriges 50 snabbast växande teknologiföretag, baserat på tillväxten i nettoomsättningen de senaste fyra åren. Rankingen inkluderar såväl publika som privata bolag och omfattar all typ av teknologi, från mjuk- och hårdvara till life science, kommunikation och clean technology. Mer information finns på: www.deloitte.se/fast50. Stillfront har sedan noteringen hösten 2015 varje kvartal uppvisat en kontinuerlig hög och lönsam intäktstillväxt rullande 12 månader. Stillfront har sedan noteringen ökat antalet så kallade kärnprodukter (dvs spel som omsätter mer än 5 MSEK i årstakt) från fyra till fjorton och antalet studios har ökat från fyra till åtta. "Stillfront har åtnjutit en enastående tillväxt de senaste åren. Vår tillväxt bygger på vår s
Payvision's annual report reveals cross-border ecommerce trends in 201719.10.2017 09:00 | Pressmeddelande
With online marketplaces and consumer technology leading the way for growth AMSTERDAM, The Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Payvision, global acquirer and data-driven omnichannel solutions provider, has published the findings of its fifth annual cross-border ecommerce research report, in collaboration with Juniper Research. The paper includes the results of a global survey of various industry players regarding the game-changers, the biggest challenges, the best practices for going cross-border, and much more. When compared to last year's findings, the report reveals a new and exciting context for global cross-border trade. The compound annual growth rate predicted for the next three years for cross-border ecommerce is now 17%, whereas it stands at just 12% for ecommerce overall. Also, over the past 12 months, merchants' attitudes towards cross-border ecommerce have become more positive, with 50% of respondents agreeing and 31% strongly
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds19.10.2017 08:00 | Pressmeddelande
Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE, Calif. and BREST, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Dravet Syndrome European Federation and Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, announced today the publication of the initial results from a landmark survey into the clinical, social and economic consequences of Dravet syndrome on children, young adults and their families in Developmental Medicine & Child Neurology [doi:10.1111/dmcn.13591]. This study was led by Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium, Head of the Pediatric Neurology Department and Director of the Childhood Epilepsy
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53 | Pressmeddelande
AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc
Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42 | Pressmeddelande
NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum